Resources from the same session
LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Presenter: Jaume Capdevila
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Presenter: Sophie Leboulleux
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Presenter: Jorge Hernando
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Presenter: Halfdan Sorbye
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1101MO - Development of CAR T-cells for future treatment of NETs
Presenter: Barbara Mandriani
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Discussion LBA67 and 1743MO
Presenter: Laura Locati
Session: Mini oral session - NETs and endocrine tumours
Resources:
Slides
Webcast